Becton Dickinson
BDX
$150.85
+0.19%
Becton, Dickinson and Co. (BDX) is a global medical technology company that manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products across four business units: Medical Essentials, Connected Care, Biopharma Systems, and Interventional. As a diversified healthcare stalwart with over 120 years of history, BDX holds leading positions in syringes, infusion pumps, and medication dispensing systems, deriving more than 60% of revenue from the United States. The current investor narrative centers on the company's ability to sustain modest revenue growth amid a challenging macro environment, with recent attention on its Q2 2026 earnings beat and raised profit outlook, though skepticism persists regarding margin expansion and competitive pressures in core segments.…
BDX
Becton Dickinson
$150.85
Related headlines
Investment Opinion: Should I buy BDX Today?
Rating: Hold. BDX is a defensive value play with a low forward P/E (11.8x) and strong free cash flow, but its decelerating growth and margin compression warrant caution. The analyst consensus is a cautious Buy with an average target implying ~23% upside, but the stock's downtrend and lack of catalysts suggest waiting for a better entry.
Supporting Evidence: The forward P/E of 11.8x is near historical lows and well below the sector median of 22x. Revenue growth of 1.6% YoY is below the industry average, but free cash flow yield of 6.2% is attractive. Gross margin improved sequentially to 44.63% from 42.81%, but net margin remains depressed at 7.27%. The implied upside to analyst EPS targets ($16.51) is 23%, but this depends on earnings recovery.
Risks & Conditions: The Hold rating would upgrade to Buy if revenue growth re-accelerates above 3% and net margin recovers above 10%, or if the stock pulls back to the 52-week low of $127.59. It would downgrade to Sell if growth turns negative or margins contract further. Overall, BDX appears fairly valued relative to its history but slightly overvalued on trailing earnings; the forward P/E suggests undervaluation if earnings materialize.
Sign up to view all
BDX 12-Month Price Forecast
BDX is a neutral opportunity: the low forward P/E provides a valuation floor, but the lack of growth catalysts and margin pressure limit upside. The base case of 2% growth and stable margins is most likely, with the stock trading in a $150-$170 range. A bullish outcome would require a clear catalyst like a major product approval or margin recovery, while a bearish outcome could materialize if growth stalls. The stance would upgrade to bullish if revenue growth exceeds 3% and net margin recovers above 10%, and downgrade to bearish if growth falls below 1% or margins contract further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $196.10 and implied upside of +30.0% versus the current price.
Average Target
$196.10
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$121 - $196
Analyst target range
BDX has coverage from 4 analysts, with a consensus leaning bullish: 2 Buy ratings, 2 Neutral/Hold ratings, and no Sell ratings. The average estimated EPS is $16.51, with a low of $16.37 and high of $16.79. The average revenue estimate is $21.875 billion, with a range of $21.732 billion to $22.165 billion. Based on the current price of $158.08, the implied upside to the average EPS target (using a forward P/E of 11.8x) is approximately 23% (target price of ~$194). However, explicit price targets are not provided; the consensus recommendation is a cautious 'Buy' with moderate conviction. The target range for EPS implies a relatively tight spread (low to high difference of 2.6%), suggesting analysts have similar expectations for near-term earnings. The high EPS estimate of $16.79 assumes margin expansion and revenue acceleration from biopharma and connected care, while the low estimate of $16.37 factors in ongoing margin pressure and slower hospital spending. Recent ratings actions show no changes in the past few months, with firms like Argus, Citigroup, and Jefferies maintaining Buy ratings, while JP Morgan and Piper Sandler hold Neutral. The lack of downgrades suggests stability, but the absence of upgrades indicates limited catalysts for near-term outperformance.
Drowning in data?
Find the real signal!
Bulls vs Bears: BDX Investment Factors
BDX presents a mixed picture: its low forward P/E (11.8x) and strong free cash flow ($2.63B) argue for value, while decelerating revenue growth (1.6% YoY) and margin compression (net margin 7.27%) raise concerns. The bull case rests on earnings recovery justifying the forward multiple, but the bear case highlights structural headwinds in hospital spending and competitive pressures. The single most important tension is whether BDX can re-accelerate revenue growth above 3% and expand margins back toward 10% net margin, which would validate the current valuation. Currently, the bearish evidence from price action and growth deceleration is stronger, but the low forward P/E provides a margin of safety.
Bullish
- Strong Free Cash Flow Yield: BDX generates $2.631 billion in trailing free cash flow, yielding approximately 6.2% at the current market cap. This robust cash generation supports the dividend (2.84% yield) and provides flexibility for debt reduction or strategic acquisitions.
- Low Forward P/E Suggests Value: The forward P/E of 11.8x is near the low end of its historical range (16x-39x trailing) and well below the sector median of ~22x. If earnings materialize as expected ($16.51 EPS), the stock offers a 23% upside to a fair value of ~$194.
- Raised Profit Outlook Signals Confidence: Following Q2 FY2026 earnings beat, management raised full-year profit guidance. This indicates operational improvements and cost discipline, with net income of $382 million in Q1 showing sequential improvement from $308 million in Q2 FY2025.
- Diversified Revenue Streams: BDX operates across four business units (Medical Essentials 35%, Connected Care 24%, Interventional 29%, Biopharma 13%), reducing reliance on any single product. Over 60% of revenue is from the U.S., providing stability in a fragmented global market.
Bearish
- Declining Revenue Growth Momentum: Revenue growth decelerated from 9.0% YoY in Q3 FY2025 to just 1.6% in Q1 FY2026 ($5.252B vs $5.168B). This slowdown is driven by sluggish hospital capital spending and competitive pressures in interventional segments.
- Margin Compression Erodes Profitability: Net margin fell to 7.27% in Q1 FY2026 from 10.42% in Q3 FY2025, while operating margin dropped to 11.31% from 16.01% over the same period. Rising R&D ($318M) and SG&A ($1.432B) costs are squeezing earnings.
- Stock in Sustained Downtrend: BDX has declined 10.8% over the past year, severely underperforming the S&P 500's +19.1% gain. The stock trades at 84% of its 52-week range, with a 6-month decline of -18.9%, indicating persistent negative momentum.
- High Payout Ratio Limits Reinvestment: The dividend payout ratio of 71.3% leaves limited retained earnings for growth investments. This could constrain R&D or M&A needed to re-accelerate top-line growth in a competitive environment.
BDX Technical Analysis
BDX is in a sustained downtrend over the past year, with a 1-year price change of -10.83%, significantly underperforming the S&P 500's +19.1% gain. The stock currently trades at $158.08, which is 84.4% of its 52-week range (low $127.59, high $187.35), positioning it closer to the lower end of the range. This suggests the stock is in a bearish phase, with potential value opportunity if fundamentals stabilize, but also risk of further downside if negative momentum persists. Short-term momentum shows a conflicting signal: the 1-month price change is +9.45%, while the 3-month change is +2.31%, indicating a recent bounce from the April lows. However, the 6-month change of -18.91% and year-to-date decline of -18.91% underscore the broader downtrend. The 1-month relative strength versus SPY is +10.70%, suggesting a short-term outperformance that may be a mean-reversion rally within a larger bear trend. The 52-week low of $127.59 serves as critical support; a break below could signal further downside toward $120. Conversely, the 52-week high of $187.35 is a key resistance level; a breakout above would indicate a trend reversal. BDX's beta of 0.271 implies it is significantly less volatile than the market, meaning the stock tends to move less than the S&P 500, which may appeal to risk-averse investors but also limits upside participation in rallies.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-14.0%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | -0.8% | +2.0% |
| 3m | -2.2% | +10.6% |
| 6m | -25.6% | +8.3% |
| 1y | -14.0% | +20.4% |
| ytd | -22.6% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory shows modest growth, with the most recent quarter (Q1 FY2026, ending Dec 2025) reporting $5.252 billion, up 1.63% year-over-year from $5.168 billion in the prior-year quarter. However, this growth rate has decelerated from the 9.0% YoY growth seen in Q3 FY2025 ($5.509 billion) and the 6.6% growth in Q4 FY2025 ($5.890 billion). The company's revenue segments—Medical ($2.4B) and Life Sciences ($2.5B)—are roughly balanced, but the overall growth is being dragged by slower hospital capital spending and competitive pressures in the interventional segment. The investment case hinges on whether BDX can re-accelerate growth through its biopharma systems and connected care platforms. Profitability remains solid but under pressure: net income for the latest quarter was $382 million, with a net margin of 7.27%, down from 10.42% in Q3 FY2025. Gross margin improved sequentially to 44.63% from 42.81% in Q2 FY2025, but remains below the 47.81% reported in Q3 FY2025. Operating margin of 11.31% is stable but below the 16.01% peak in Q3 FY2025, indicating cost headwinds from R&D and SG&A expenses. The company is profitable, but margin compression is a concern for earnings growth. BDX maintains a healthy balance sheet with a debt-to-equity ratio of 0.755 and a current ratio of 1.11, indicating adequate liquidity. Free cash flow (TTM) is $2.631 billion, providing a free cash flow yield of approximately 6.2% based on the current market cap. The company generated $657 million in operating cash flow in the latest quarter, covering capital expenditures of $108 million. ROE stands at 6.61%, which is modest but reflects the capital-intensive nature of the medical device industry. The payout ratio of 71.3% suggests a sustainable dividend, but limits retained earnings for growth investments.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+1.63%
YoY Comparison
Gross Margin
44.63%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Since BDX has positive net income ($382 million in the latest quarter), the primary valuation metric is the P/E ratio. The trailing P/E is 25.2x, while the forward P/E is 11.8x, implying the market expects significant earnings growth in the coming year. The wide gap between trailing and forward P/E suggests that the current earnings are depressed, and analysts anticipate a sharp recovery, which could be due to one-time charges or cyclical factors. Compared to the industry average (Medical Instruments & Supplies), BDX's trailing P/E of 25.2x is at a premium to the sector median of approximately 22x (based on available data), representing a 14.5% premium. This premium may be justified by BDX's diversified product portfolio and strong free cash flow generation, but the premium is modest given the company's below-average revenue growth. Historically, BDX's trailing P/E has ranged from roughly 16x to 39x over the past five years. The current 25.2x is near the middle of this range, suggesting the stock is fairly valued relative to its own history. However, the forward P/E of 11.8x is near the lower end of historical forward multiples, indicating that if earnings materialize as expected, the stock could be undervalued. The PEG ratio of -37.0 is not meaningful due to negative earnings growth expectations, but the low forward P/E hints at potential value.
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~107x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BDX's net margin has compressed from 10.42% in Q3 FY2025 to 7.27% in Q1 FY2026, reflecting cost headwinds from R&D ($318M) and SG&A ($1.432B). The high payout ratio of 71.3% limits retained earnings for reinvestment, while debt-to-equity of 0.755 is manageable but not negligible. Revenue concentration in the U.S. (over 60%) exposes the company to domestic healthcare policy changes and hospital budget cycles. Free cash flow of $2.63B provides a buffer, but if growth continues to decelerate, the stock's valuation could de-rate further.
Market & Competitive Risks: BDX trades at a trailing P/E of 25.2x, a 14.5% premium to the sector median of ~22x, which may compress if growth disappoints. The stock's beta of 0.271 limits downside but also means it lags in market rallies, as seen by its -10.8% 1-year return vs. S&P 500 +19.1%. Competitive pressures in interventional (29% of sales) and slower hospital capital spending are key headwinds. Recent news of a raised profit outlook provides some support, but analyst skepticism persists with no upgrades.
Worst-Case Scenario: If revenue growth stalls below 1% and margins continue to compress, the stock could fall to its 52-week low of $127.59, representing a -19.3% decline from the current price of $158.08. In a severe recession, historical max drawdown of -33% would imply a price near $106, a -33% loss. The bear case is amplified if the company cuts its dividend or issues a negative pre-announcement.
FAQ
The primary risks are: 1) Financial: margin compression (net margin fell to 7.27% from 10.42% in six months) and a high payout ratio of 71.3% limiting reinvestment. 2) Competitive: pressure in interventional (29% of sales) and slower hospital capital spending. 3) Macro: low beta (0.271) means the stock underperforms in rallies, and a recession could further pressure hospital budgets. 4) Company-specific: reliance on U.S. market (60% of revenue) exposes it to healthcare policy changes. The most severe risk is a dividend cut if cash flow deteriorates, which could trigger a sell-off toward the 52-week low of $127.59.
The 12-month outlook is balanced: a 50% probability base case sees the stock trading between $150-$170, assuming 2% revenue growth and stable margins. The bull case (25% probability) targets $175-$195 if growth re-accelerates and margins expand. The bear case (25% probability) targets $128-$145 if growth stalls and margins compress further. The most likely scenario is the base case, with the stock near $158. The key assumption is that earnings meet the $16.51 consensus, which would support the current valuation. Upside catalysts include a strong Q3 earnings beat, while downside risks include a guidance cut.
BDX's trailing P/E of 25.2x is at a 14.5% premium to the sector median of ~22x, suggesting it is slightly overvalued on past earnings. However, the forward P/E of 11.8x is near the low end of its historical range (16x-39x trailing) and implies the market expects significant earnings growth. If analysts' $16.51 EPS estimate is achieved, the stock would be undervalued with a target price of ~$194. The PEG ratio is negative due to declining earnings, so it is not meaningful. Overall, BDX appears fairly valued on a forward basis but overvalued on trailing earnings, making it a value play contingent on earnings recovery.
BDX offers a compelling risk/reward at current levels due to its low forward P/E of 11.8x and 6.2% free cash flow yield, but the stock is in a downtrend with decelerating revenue growth (1.6% YoY). For long-term value investors with a 3-5 year horizon, it could be a good buy if you believe earnings will recover to $16.51 EPS. However, growth investors may find better opportunities elsewhere. The biggest downside risk is further margin compression, which could push the stock to its 52-week low of $127.59. Overall, it's a cautious buy for patient, income-focused investors.
BDX is better suited for long-term investment due to its low beta (0.271), stable dividend yield (2.84%), and defensive business model. Short-term traders may find limited upside given the stock's downtrend and lack of catalysts. The suggested minimum holding period is 3-5 years to allow for earnings recovery and multiple expansion. With a forward P/E of 11.8x, the stock offers value for patient investors, but those seeking quick gains should look elsewhere. The low volatility makes it a portfolio stabilizer rather than a growth driver.
